Company news
Orion Corp. news in 2026
Orion Corp.'s news releases, calls and decks from 2026, newest first.
Orion Corporation completed share acquisitions
September 30, 2026
Orion Corporation: Acquisition of own shares during week 40, 2026
September 30, 2026
Orion Corporation: Acquisition of own shares during week 39, 2026
September 25, 2026
Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026
July 3, 2026
105,950 Orion Corporation A shares converted into B shares
May 15, 2026
Composition of the Nomination Committee of Orion Corporation
April 27, 2026
Orion Group Interim report January–March 2026
April 23, 2026
Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours
April 23, 2026
Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA
April 20, 2026
Orion publishes Interim Report for January–March 2026 and holds a webcast on 23 April 2026
April 10, 2026
Change in Orion Group Executive Team as of 8 April 2026 – Berkeley Vincent appointed Executive Vice President, Innovative Medicines
April 1, 2026
Decisions taken by Orion Corporation's Annual General Meeting and Board of Directors' organising meeting on 24 March 2026
March 24, 2026
Peace through well-being: Orion and CMI - Martti Ahtisaari Peace Foundation announce partnership
March 18, 2026
Orion Corporation: Transfer of 172,778 own B shares on 10 March 2026
March 10, 2026
Orion Group Financial Statement documents 2025 and Remuneration Report published
February 27, 2026
The Board of Directors of Orion Corporation decided on a new plan period for the Long-term Incentive program for the company’s key persons
February 12, 2026
Notice to the Annual General Meeting of Orion Corporation
February 12, 2026
Orion Group Financial Statement Release January–December 2025
February 12, 2026
62,752 Orion Corporation A shares converted into B shares
February 3, 2026
Orion publishes Financial Statement Release for 2025 and holds a webcast on 12 February 2026
January 30, 2026
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
January 20, 2026
182,827 Orion Corporation A shares converted into B shares
January 16, 2026
Recommendation by the Orion Nomination Committee on the proposals to be presented to the 2026 Annual General Meeting
January 15, 2026
Orion updates time estimate for the potential related to the annual Nubeqa® net sales recorded by Orion
January 14, 2026
Inside information: Orion provides outlook for 2026 and estimates that the annual Nubeqa® net sales recorded by Orion has potential to exceed EUR 1 billion in the future
January 14, 2026
Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE)
January 8, 2026